Aurinia Pharmaceuticals Inc stock is traded at $17.11, with a volume of 1,477,088. It is up +3.32% in the last 24 hours and up +8.09% over the past month. Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Previous Close:
$16.56
Open:
$16.88
24h Volume:
1,477,088
Relative Volume:
1.58
Market Cap:
$2.29B
Revenue:
$298.30M
Net Income/Loss:
$298.21M
P/E Ratio:
7.91
EPS:
$2.16
Net Cash Flow:
$166.93M
1W Performance:
-1.44%
1M Performance:
+8.09%
6M Performance:
+8.50%
1Y Performance:
+19.90%
1-Day Range:
$16.56$17.40
1-Week Range:
$15.95$17.40
52-Week Range:
$13.33$19.25
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
250-744-2487Address
#140, 14315 - 118 AVENUE, EDMONTON, BC, CanadaMarket Cap
Revenue
Net Income
Cash Flow
EPS